| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
No specific biological target has been identified for Boc-Inp-OH, as it functions primarily as a synthetic building block rather than a direct pharmacological agent. However, the compound's piperidine core is a common motif in pharmaceuticals that interact with various biological targets including GPCRs, ion channels, and enzymes. The compound serves as a versatile building block for the synthesis of various biologically active molecules. Its Boc-protected piperidine allows for the introduction of the piperidine ring into drug candidates, which can modulate pharmacokinetic properties, enhance binding affinity, and improve metabolic stability. The compound's derivatives may target diverse biological pathways including neurotransmitter receptors, enzymes, and transporters. In peptide synthesis, the compound is used to introduce piperidine-4-carboxylic acid residues into peptide sequences, potentially affecting peptide conformation and biological activity.
|
|---|---|
| ln Vitro |
It serves as a pharmacological bridge. When isopipixic acid's camptothecin ester is mounted onto a triazine dendrimer intermediate made via an iterative, scalable process, a cationic and PEGylated target is produced that has activity in cell culture similar to that of the free Drugs.
In vitro, Boc-Inp-OH is used as a versatile building block for the synthesis of various biologically active molecules. It is a biochemical compound that could be utilized as a biomaterial or organic/chemical reagent for biomedical research. In peptide synthesis, the compound is used to introduce piperidine-4-carboxylic acid residues into peptide sequences. In medicinal chemistry, it serves as a building block for the synthesis of piperidine-containing drug candidates. Its Boc-protected amine allows for selective deprotection under acidic conditions, enabling further functionalization. The carboxylic acid group allows for amidation, esterification, and other transformations to produce a diverse range of compounds. In organic synthesis, it is used as a versatile building block for creating complex molecules efficiently. |
| Enzyme Assay |
Cell-free assays for Boc-Inp-OH are focused on its use as a chemical reagent. Standard protocols for peptide synthesis involve coupling the compound with amino acids or peptides using coupling reagents such as HATU, HOBt, or EDC, followed by Boc deprotection with TFA. The reaction progress is monitored by HPLC or MS. For the synthesis of piperidine-containing drug candidates, the compound is used as a starting material in multi-step synthetic routes. The compound's reactivity can be studied using various analytical techniques including NMR spectroscopy, mass spectrometry, and HPLC. Its use in medicinal chemistry involves standard organic synthesis procedures.
|
| Cell Assay |
Cellular assays are not performed with the parent compound Boc-Inp-OH. Instead, its derivatives, such as piperidine-containing drug candidates, are evaluated in cell-based systems for various biological activities. The parent compound itself is not used as a test article in cell-based experiments due to its role as a synthetic building block. Instead, it is used in the synthesis of drug candidates that are subsequently tested in cellular assays.
|
| Animal Protocol |
Animal studies are not conducted with the parent compound Boc-Inp-OH. Its derivatives may be evaluated in animal models for therapeutic efficacy, but the parent compound itself is not administered to animals. The compound is a synthetic intermediate and is not intended for therapeutic use.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Boc-Inp-OH are not available, as the compound is primarily a chemical intermediate rather than a drug candidate. With a molecular weight of 229.27 g/mol, the compound would be expected to have moderate membrane permeability if administered. However, comprehensive pharmacokinetic studies including absorption, distribution, metabolism, and excretion have not been performed, as the compound is not intended for therapeutic use. For research purposes, the compound is typically handled as a neat chemical and not administered to living organisms for pharmacokinetic profiling.
|
| Additional Infomation |
Boc-Inp-OH is a research chemical, not an approved drug. It has no clinical trial or marketing approval status for therapeutic use. The compound is a piperidine derivative that serves as a versatile building block for the synthesis of various biologically active molecules. It is a biochemical compound that could be utilized as a biomaterial or organic/chemical reagent for biomedical research. The compound has a molecular formula of C11H19NO4 and a molecular weight of 229.27 g/mol. It has a purity of ≥99.0% by HPLC and appears as a solid. It should be stored at room temperature. The compound is for research use only and not for human use.
|
| Molecular Formula |
C11H19NO4
|
|---|---|
| Molecular Weight |
229.27
|
| Exact Mass |
229.131
|
| CAS # |
84358-13-4
|
| PubChem CID |
392871
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
353.2±35.0 °C at 760 mmHg
|
| Melting Point |
149-153ºC
|
| Flash Point |
167.4±25.9 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.496
|
| LogP |
1.04
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
16
|
| Complexity |
274
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(N1CCC(C(O)=O)CC1)OC(C)(C)C
|
| InChi Key |
JWOHBPPVVDQMKB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H19NO4/c1-11(2,3)16-10(15)12-6-4-8(5-7-12)9(13)14/h8H,4-7H2,1-3H3,(H,13,14)
|
| Chemical Name |
1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3617 mL | 21.8083 mL | 43.6167 mL | |
| 5 mM | 0.8723 mL | 4.3617 mL | 8.7233 mL | |
| 10 mM | 0.4362 mL | 2.1808 mL | 4.3617 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
